In the present scenario, immunization is of utmost importance as it keeps us safe and
protects us from infectious agents. Despite the great success in the field of vaccinology …

In spite of current influenza vaccines being immunogenic, evolution of the influenza virus
can reduce efficacy and so influenza remains a major threat to public health. One approach …

Adjuvants enhance immunity to vaccines and experimental antigens by a variety of
mechanisms. In the past decade, many receptors and signaling pathways in the innate …

Inhibition of the mammalian target of rapamycin (mTOR) pathway extends life span in all
species studied to date, and in mice delays the onset of age-related diseases and …

Emulsion adjuvants such as MF59 and AS03 have been used for more than two decades as
key components of licensed vaccines, with over 100 million doses administered to diverse …

Background In the elderly, traditional influenza inactivated vaccines are often only modestly
immunogenic, owing to immunosenescence. Given that adjuvantation is a means of …

The rapid development of a SARS-CoV-2 vaccine is a global priority. Here, we develop two
capsid-like particle (CLP)-based vaccines displaying the receptor-binding domain (RBD) of …

The COVID-19 pandemic is a shocking reminder of how our world would look in the
absence of vaccination. Fortunately, new technologies, the pace of understanding new and …

The first clinical trial of an MF59®-adjuvanted influenza vaccine (Novartis) was conducted
20 years ago in 1992. The product that emerged (Fluad®, Novartis) was licensed first in Italy …

Accumulated evidence obtained from various clinical trials and animal studies suggested
that cancer vaccines need better adjuvants than those that are currently licensed, which …